LYCOS RETRIEVER 
Videx: Retrovir
built 272 days ago
Therapy with Videx can cause certain changes (mutations) in HIV's structure to occur. Some mutations will prevent Videx from working against HIV. Some studies suggest that HIV is much more likely to become resistant to Videx if it is already resistant to Retrovir (AZT), another NRTI. If HIV is not resistant to Retrovir, resistance to Videx may develop much more slowly. If HIV does become resistant to Videx, it will not likely be sensitive to Hivid (ddC), another NRTI. However, this is not the same the other way around: HIV that becomes resistant to Hivid may still be sensitive to Videx.
Source:
Background: Researchers at the National Cancer Institute (NCI) first identified Videx's potential as a treatment for HIV in 1985. The NCI began the first clinical trial of Videx in 1988, and then licensed the drug to Bristol-Myers Squibb on an exclusive basis. Early studies showed that taking Videx alone was slightly better than taking Retrovir (AZT) alone, particularly for people who had already taken Retrovir.
Source:
An early pivotal study, ACTG 175, compared Retrovir alone, Videx alone, Retrovir plus Videx, and Retrovir plus Hivid. This study included 18% women, or about 444 women out of 2,467 total participants.
Source:
MORE ABOUT
Retrovir